Active Investments

Aclaris Therapeutics
Specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies.
Aerie Pharmaceuticals
Clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma.(NASDAQ:AERI)
Alimera Sciences
Specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.(NASDAQ:ALIM)
Alvine
Developing biologics to target celiac disease. Partnered with Abbvie.
Amarin
Focused on improving the treatment of cardiovascular disease. The company’s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease. (NASDAQ: AMRN)
Anthera Pharmaceuticals
Focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. (NASDAQ: ANTH)
Ascendis Pharma
Ascendis Pharma develops differentiated prodrug versions of high-value protein drugs, such as growth hormone. (NASDAQ:ASND)
Ascenta Therapeutics
Ascenta is a clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer. Ascenta’s current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis). Ascenta’s lead drug candidate, AT-101) is currently in Phase 2b clinical trials.
aTyr Pharma
aTyr Pharma is a privately held company focused on the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. aTyr’s key programs are currently focused on severe, rare diseases characterized by immune dysregulation, for which there are currently limited or no treatment options.
Audentes Therapeutics
Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare diseases through the application of gene therapy technology.
Auris Medical
Auris Medical (NASDAQ:EARS) is a Swiss biotechnology company developing specific pharmaceutical compounds for the prevention or treatment of inner ear disorders, an area of great unmet medical need. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. The company has completed successful Phase IIb clinical trials in both tinnitus and acute hearing loss.
Catalyst Biosciences
Catalyst is a drug discovery and development company that is creating novel catalytic biopharmaceutical products based on engineered human proteases. The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Catalyst is developing both natural and engineered human proteases "Alterase Therapeutics" to treat major diseases.
Coherus Biosciences
Coherus Biosciences (NASDAQ:CHRS) is a biosimilar platform company that acquired Intekrin in Q1 2014. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases.The Company has built a capital efficient infrastructure capable of taking products from cell lines to approved labels.
First Aid Shot Therapy
Based in Burlingame, California, privately held First Aid Shot Therapy(R), Inc. is focused on the development and commercialization of a comprehensive portfolio of OTC pharmaceutical products in liquid 'shot' (40ml / 1.35oz.) format. The F.A.S.T. team is comprised of consumer product executives that have been responsible for the launch and commercial success of products such as VitaminWater and Pretzel Crisps. F.A.S.T.'s products are formulated by the Company's proprietary research and development organization, F.A.S.T. Labs(tm).
Histogenics
Histogenics (NASDAQ:HSGX) is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. Histogenics’ flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility.
Hyperion Therapeutics
Hyperion (NADSAQ: HPTX) is a pharmaceutical company focused on the development of treatments that address critical unmet needs in the areas of gastroenterology and hepatology. Hyperion aims to build its portfolio of products through partnership and in-licensing. Hyperion is currently focused on the development of one compound, glycerol phenybutyrate (HPN-100), for both urea cycle disorders (UCD) and hepatic encephalopathy (HE). The compound is currently in approved and in commercial stage for UCD and in Phase 2 studies for HE.
Innocoll
Innocoll (NASDAQ:INNL) is a global, commercial-stage, specialty pharmaceutical company. Innocoll develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies.
Marinus Pharmaceuticals
Marinus (NASDAQ:MRNS) is a specialty pharmaceutical company dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological, psychiatric, and pain disorders. The company’s lead product is a first-in-class therapy for epilepsy.
Mirna Therapeutics
Mirna is harnessing the power of tumor suppressor microRNAs (miRNAs) to kill cancer cells by regaining control over multiple oncogenic pathways. Mirna’s MRX34 is in clinical studies for solid and hematologic cancers, and is the first microRNA in immune-oncology clinical trials.
Natera
Natera is a privately-held, commercial stage genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to help families diagnose and manage genetic disease.
NuCana
NuCana is a clinical stage biopharmaceutical company developing and commercialising novel anti-cancer medicines. With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative treatments. NuCana is transforming cancer agents (nucleoside analogues) into better and safer medicines that overcome key resistance mechanisms.
ObsEva
ObsEva is a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women’s reproductive medicine. ObsEva’s main focus is on therapies for preterm labour.
Ocera
Ocera (NASDAQ:OCRX) is a biopharmaceutical company focused on the licensing, development and commercialization of proprietary compounds to treat a broad range of gastrointestinal and liver diseases. Ocera is pursuing the development of AST-120 in Crohn's disease and other gastrointestinal and liver diseases including pouchitis, hepatic encephalopathy, irritable bowel syndrome and proton pump inhibitor-resistant gastroesophageal reflux disease.
Ophthotech Corporation
Ophthotech (NASDAQ:OPHT) is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the eye. The company’s most advanced product candidate is Fovista™ anti-PDGF therapy, which it is developing for use in combination with anti-VEGF drugs that represent the standard of care for the treatment of wet age-related macular degeneration.
Principia Biopharma
Principia Biopharma is a privately-held biopharmaceutical company focused on discovering and developing first-in-class small molecule drugs within the fields of autoimmune disease and oncology that are potent, safe and have antibody-like specificity for their targets.
Prothena Corporation
Prothena Corporation plc (Nasdaq: PRTA) is a clinical-stage biotechnology company that is advancing and developing novel antibodies for broad range of diseases involving protein misfolding or cell adhesion. The company’s lead program is targeting orphan disease amyloidosis.
Spark Therapeutics
Spark Therapeutics (NASDAQ: ONCE) is a public biotech company focused on developing curative, one-time gene therapy products with the potential to transform the lives of patients and re-imagine the treatment of debilitating diseases. Spark's lead gene therapy candidate, for RPE65-related blindness, is currently in Phase 3 clinical trials. www.sparktx.com.
Versartis, Inc.
Versartis, Inc. (NASDAQ:VSAR) is a biotechnology company developing therapeutics for the treatment of endocrine disorders. The company’s lead product candidate is VRS-317, a novel long-acting form of human growth hormone. New compounds developed by Versartis using the XTEN technology are expected to provide improved therapeutic outcomes such as enhanced efficacy/compliance, fewer side effects, prolonged half-life (up to monthly dosing), as well as low-cost production and enhanced stability.
ZS Pharma
ZS Pharma (NASDAQ:ZSPH) is a public specialty pharmaceutical company focused on the treatment of kidney and liver diseases. ZS Pharma’s lead compound (ZS-9) is targeting hyperkalemia, a life-threatening metabolic condition characterized by an abnormally high serum concentration of potassium, and is currently in Phase 3 trials.